Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.55 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296263 | 0.85 | NR4A2 (0.67) | MCL1ACMSDMAOBMRGPRX4NR4A2 | |
| SCHEMBL3294945 | 0.85 | ANO1 (0.60) | MCL1ACMSDMAOBMRGPRX4NR4A2 | |
| SCHEMBL9534579 | 0.80 | MCL1 (0.78) | MCL1ACMSDNR4A2 | |
| SCHEMBL1519064 | 0.80 | MAOB (0.77) | MCL1MAOBNR4A2MAOA | |
| SCHEMBL3299012 | 0.80 | NR4A2 (0.70) | MRGPRX4NR4A2CYP4F2CYP4A11 | |
| SCHEMBL1745416 | 0.80 | FFAR1 (0.74) | FFAR1FFAR4 | |
| SCHEMBL25309677 | 0.79 | MRGPRX4 (0.60) | MCL1MAOBMRGPRX4MAOA | |
| SCHEMBL3296016 | 0.79 | NR4A2 (0.54) | MCL1MAOBMRGPRX4NR4A2FFAR1 | |
| SCHEMBL3294951 | 0.78 | FFAR1 (0.54) | MAOBMRGPRX4CYP4F2CYP4A11FFAR1 | |
| SCHEMBL3299848 | 0.78 | MAOB (0.62) | MCL1MAOBMRGPRX4NR4A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | MCL1 2555/4885ACMSD 3931/4885MAOB 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.